Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2018 According to a Corbus Pharmaceuticals media release, the company expects to report topline results for this study in the first half of 2020.
    • 08 Aug 2018 According to a Corbus Pharmaceuticals media release, this study was designed with input from the Therapeutic Development Network of the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society Clinical Trials Network. FDA provided guidance on the overall study design.
    • 14 Jun 2018 According to a Corbus Pharmaceuticals media release, in support of this study, Corbus received a Development Award for up to $25 million from the Cystic Fibrosis Foundation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top